Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis

Glomerulosclerosis, Focal Segmental Clinical Trial

Official title:
A Phase 2a, Open-label, Single-arm, 2-Part Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis

Status Completed

Clinical Trial Summary

This study will evaluate the efficacy, safety and pharmacokinetics (PK) of VX-147 in participants with apolipoprotein L1 (APOL1)-mediated focal segmental glomerulosclerosis (FSGS).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Glomerulosclerosis, Focal Segmental

Clinical Trial Details

NCT number	NCT04340362
Study type	Interventional
Source	Vertex Pharmaceuticals Incorporated
Contact
Status	Completed
Phase	Phase 2
Start date	June 8, 2020
Completion date	December 9, 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00098020` - Podocyte Retinoids	Phase 2
Terminated	`NCT04387448` - A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease	Phase 2
Completed	`NCT02000440` - A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)	Phase 2
Terminated	`NCT04235621` - A Study to Understand the Genetics and Clinical Course of Focal Segmental Glomerulosclerosis (FSGS), Treatment-Resistant Minimal Change Disease (TR-MCD), and Diabetic Nephropathy (DN)
Recruiting	`NCT01209000` - Nephrotic Syndrome Study Network
Recruiting	`NCT05505500` - Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome.
Recruiting	`NCT03949972` - The FOrMe Registry (The German Focal Segmental Glomerulosclerosis and Minimal Change Disease Registry)